Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Every story we pull is tagged to the disease it’s about — so you can filter to your condition and read only what matters.
20 earlier
Infinimmune, a California startup, is developing treatments it claims might last longer and be more effective than existing atopic dermatitis medications.
Original title: “Chasing Dupixent, a biotech aims to make better antibody drugs for eczema”
Despite earlier claims of improvement at the fill-finish plant, the FDA has classified the facility as Official Action Indicated based on inspection findings.
Original title: “Scholar Rock rejigs approval filing after FDA flags violations at Novo plant”
Insilico Medicine CEO Alex Zhavoronkov’s mad dash across the BIO International Convention in June attracted plenty of eyes. But the executive would prefer industry watchers gawk at the billions of dollars’ worth of deals his company has struck.
Original title: “After billions in deals, Insilico CEO promises: ‘You haven't seen anything yet’”
Epicrispr Biotechnologies is working on an epigenetic medicine for facioscapulohumeral muscular dystrophy, while Infinimmune will advance a pair of antibodies for atopic dermatitis.
Original title: “Epicrispr, Infinimmune snag combined $165M in VC cash”
The startup has completed enrollment of an early-stage study testing a first-of-its-kind treatment for facioscapulohumeral muscular dystrophy, a disease targeted by many other drugmakers.
Original title: “Epicrispr lands $90M to advance epigenetic editing drug for rare muscle disease”
The startup is one of at least a few young companies zeroing in on the rare bleeding disorder, hereditary hemorrhagic telangiectasia, with a more precise AKT blocker.
Original title: “Vaderis hauls in $152M to test an AKT-targeting drug”
The national growth vehicle isn’t biotech‑dedicated, but channeling capital toward life sciences would amplify Austria’s strong research hubs, nondilutive funding landscape and reputation as a champion in science and technology.
Original title: “Austria’s new growth fund could further bolster its dynamic biotech innovation economy”
A surprise flop in Phase 2a cystic fibrosis trial sent Sionna’s shares plummeting, but for Vertex, the news reinforced its standard-of-care standing with highly successful drugs like Trikafta.
Original title: “Sionna’s cystic fibrosis failure is a windfall for Vertex’s blockbuster franchise”
Jazz Pharmaceuticals is reaching into its wallet once again, this time buying Actio Biosciences and an experimental therapy for KCNT1+ epilepsy, a form of the disease with no FDA-approved treatments.
Original title: “Jazz commits up to $1.3B to buy Actio, bolster epilepsy pipeline”
BioMarin’s discontinued drug showed biomarker benefits in a Phase 3 study for ENPP1 deficiency but these failed to translate to clinical improvements.
Original title: “BioMarin axes asset from $270M Inozyme takeover, ending run in rare metabolic indication”